Shenfu Injection (参附注射液) suppresses inflammation by targeting haptoglobin and pentraxin 3 in rats with chronic ischemic heart failure

Chinese Journal of Integrative Medicine

Volumn 21, Issue 1, 2015, Pages 22-28

  Zheng, Si dao ^a   Wu, Hong jin ^a   Yu, Shao ping ^a   Ren, Jian xun ^a   Duo, Wei wei ^a   Ma, Zeng chun ^b   Gao, Yue ^b   Wang, Sheng qi ^b   Liu, Yu na ^a  

^a Beijing Integrated Traditional and Western Hospital   (China)

^b BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

chronic heart failure; haptoglobin; pentraxin 3; proteomics; Shenfu Injection

Indexed keywords

40S RIBOSOMAL PROTEIN; ALPHA 1 ANTITRYPSIN; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; CHINESE DRUG; HAPTOGLOBIN; PENTRAXIN 3; RIBOSOME PROTEIN; SERUM ALBUMIN; SHENFU INJECTION; SODIUM CHLORIDE; UNCLASSIFIED DRUG; C REACTIVE PROTEIN; HERBACEOUS AGENT; PLASMA PROTEIN; PROTEOME; SERUM AMYLOID P; SHEN-FU;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CORONARY ARTERY LIGATION; DOWN REGULATION; HEART FAILURE; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE PRESSURE; HEMODYNAMIC PARAMETERS; INFLAMMATION; LEFT CORONARY ARTERY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; SYSTOLIC BLOOD PRESSURE; TWO DIMENSIONAL ELECTROPHORESIS; UPREGULATION; ANIMAL; BLOOD; CHRONIC DISEASE; COMPLICATION; HEART FUNCTION TEST; HEMODYNAMICS; MASS SPECTROMETRY; METABOLISM; MYOCARDIAL ISCHEMIA; PH; PHYTOTHERAPY; THREE DIMENSIONAL IMAGING; TWO DIMENSIONAL GEL ELECTROPHORESIS; WISTAR RAT;

ANIMALS; BLOOD PROTEINS; C-REACTIVE PROTEIN; CHRONIC DISEASE; DRUGS, CHINESE HERBAL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HAPTOGLOBINS; HEART FAILURE; HEART FUNCTION TESTS; HEMODYNAMICS; HYDROGEN-ION CONCENTRATION; IMAGING, THREE-DIMENSIONAL; INFLAMMATION; MALE; MYOCARDIAL ISCHEMIA; PHYTOTHERAPY; PROTEOME; RATS, WISTAR; SERUM AMYLOID P-COMPONENT; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84896084466     PISSN: 16720415     EISSN: 19930402     Source Type: Journal    
DOI: 10.1007/s11655-013-1440-8     Document Type: Article

References (42)

1. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005;46:e1–e82.
2. Niebauer J. Effects of exercise training on inflammatory markers in patients with heart failure. Heart Fail Rev 2008;13:39–49.
3. Torre-Amione G. Immune activation in chronic heart failure. Am J Cardiol 2005;95(11A):3C–8C.
4. Shah AM, Mann DL. In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet 2011;378:704–712.
5. Aukrust P, Gullestad L, Ueland T, Damas JK, Yndestad A. Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implications. Ann Med 2005;37:74–85.
6. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002;91:988–998.
7. Wu Y, Xia ZY, Meng QT, Zhu J, Lei S, Xu J, et al. Shen-Fu injection preconditioning inhibits myocardial ischemiareperfusion injury in diabetic rats: activation of eNOS via the PI3K/Akt pathway. J Biomed Biotechnol 2011;2011:384627.
8. Wang YL, Wang CY, Zhang BJ, Zhang ZZ. Shenfu injection suppresses apoptosis by regulation of Bcl-2 and caspase-3 during hypoxia/reoxygenation in neonatal rat cardiomyocytes in vitro. Mol Biol Rep 2009;36:365–370.
9. Zheng CD, Min S. Cardioprotection of Shenfu Injection against myocardial ischemia/reperfusion injury in open heart surgery. Chin J Integr Med 2008;14:10–16.
10. Zhang BJ, Wang YL, Wang CY. Effect of Shenfu Injection on nuclear factor-kappaB during myocardial ischemia/reperfusion injury in rats. Chin J Traumatol (Chin) 2005;8:200–204.
11. Cao J, Zheng CD, Zhang GX, Zhang YJ, Min S. Protective effect of Shenfu Injection on myocardial mitochondria injured by ischemia-reperfusion in rabbits. Chin Med J 2005;118:505–507.
12. Ji XF, Yang L, Zhang MY, Li CS, Wang S, Cong LH. Shen-Fu Injection attenuates post-resuscitation myocardial dysfunction in a porcine model of cardiac arrest. Shock 2011;35:530–536.
13. Luo J, Min S, Wei K, Cao J. Ion channel mechanism and ingredient bases of Shenfu Decoction’s cardiac electrophysiological effects. J Ethnopharmacol 2008;117:439–445.
14. Luo XY, Zhang FR, He RM. Efficacy of Shenfu Injection as adjuvant therapy in treating patients of ischemic cardiomyopathy with heart insufficiency. Chin J Integr Tradit West Med (Chin) 2009;29:685–687.
15. Hu YH, Wu HQ, Qi X. Influence of Shenfu Injection on heart function and bone marrow stem cell mobilization in patients with chronic heart failure of coronary heart disease. Chin J Integr Tradit West Med (Chin) 2009;29:309–312.
16. Wang J, Qiao LF, Yang GT. Role of Shenfu Injection in rats with systemic inflammatory response syndrome. Chin J Integr Med 2008;14:51–55.
17. Ke DZ, Chen QW, Li CL, Li GQ. Cytokines mechanism of Shenfu Injection in treatment of cardiogenic shock in canine. China J Chin Mater Med (Chin) 2007;32:2273–2277.
18. Maki T, Nasa Y, Tanonaka K, Takahashi M, Takeo S. Beneficial effects of sampatrilat, a novel vasopeptidase inhibitor, on cardiac remodeling and function of rats with chronic heart failure following left coronary artery ligation. J Pharmacol Exp Ther 2003;305:97–105.
19. Wu HJ, Zhang YL. The effects of Shenfu Injection on apoptosis related factors in rat model of heart failure. Chin J Integr Med Cardio/Cerebrovasc Dis (Chin) 2009;7:926–928.
20. Kinugawa S, Tsutsui H, Hayashidani S, Ide T, Suematsu N, Satoh S, et al. Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: role of oxidative stress. Circ Res 2000;87:392–398.
21. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248–254.
22. Kwak JY, Ma TZ, Yoo MJ, Choi BH, Kim HG, Kim SR, et al. The comparative analysis of serum proteomes for the discovery of biomarkers for acute myeloid leukemia. Exp Hematol 2004;32:836–842.
23. Shevchenko A, Chernushevic I, Wilm M, Mann M. “De novo” sequencing of peptides recovered from in-gel digested proteins by nanoelectrospray tandem mass spectrometry. Mol Biotechnol 2002;20:107–118.
24. Ying W, Zhang K, Qian X, Xie L, Wang J, Xiang X, et al. Proteome analysis on an early transformed human bronchial epithelial cell line, BEP2D, after alpha-particle irradiation. Proteomics 2003;3:64–72.
25. Lim H, Eng J, Yates JR, 3rd, Tollaksen SL, Giometti CS, Holden JF, et al. Identification of 2D-gel proteins: a comparison of MALDI/TOF peptide mass mapping to mu LC-ESI tandem mass spectrometry. J Am Soc Mass Spectrom 2003;14:957–970.
26. Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T, et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 2008;155:75–81.
27. Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2002;22:e10–e14.
28. Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004;110:2349–2354.
29. Kotooka N, Inoue T, Aoki S, Anan M, Komoda H, Node K. Prognostic value of pentraxin 3 in patients with chronic heart failure. Int J Cardiol 2008;130:9–22.
30. Matsubara J, Sugiyama S, Nozaki T, Sugamura K, Konishi M, Ohba K, et al. Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J Am Coll Cardiol 2011;57:861–869.
31. Kaess BM, Vasan RS. Heart failure: pentraxin 3—a marker of diastolic dysfunction and HF? Nat Rev Cardiol 2011;8:246–248.
32. Ishino M, Takeishi Y, Niizeki T, Watanabe T, Nitobe J, Miyamoto T, et al. Risk stratification of chronic heart failure patients by multiple biomarkers: implications of BNP, H-FABP, and PTX3. Circ J 2008;72:1800–1805.
33. Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand JL, Cohen-Tervaert JW, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009;11:119–129.
34. Quaye IK. Haptoglobin, inflammation and disease. Trans R Soc Trop Med Hyg 2008;102:735–742.
35. Fouad FM, Mamer O, Sauriol F, Khayyal M, Lesimple A, Ruhenstroth-Bauer G. Cardiac heart disease in the era of sucrose polyester, Helicobacter pylori and Chlamydia pneumoniae. Med Hypotheses 2004;62:257–267.
36. Suleiman M, Aronson D, Asleh R, Kapeliovich MR, Roguin A, Meisel SR, et al. Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes 2005;54:2802–2806.
37. Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. Haptoglobin and risk of myocardial infarction, stroke, and congestive heart failure in 342,125 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). Ann Med 2009;41:522–532.
38. Wang Y, Zhou Y, Meng L, Lu X, Ou N, Li X. Inflammatory mediators in Chinese patients with congestive heart failure. J Clin Pharmacol 2009;49:591–599.
39. van Empel VP, Bertrand AT, Hofstra L, Crijns HJ, Doevendans PA, De Windt LJ. Myocyte apoptosis in heart failure. Cardiovasc Res 2005;67:21–29.
40. Song WT, Cheng FF, Xu, L, Lin CR, Liu JX. Chinese medicine Shenfu Injection for heart failure: a systematic review and meta-analysis. Evid Based Complement Alternat Med 2012;2012:713149.
41. Dasgupta A, Reyes MA. Effect of Brazilian, Indian, Siberian, Asian, and North American ginseng on serum digoxin measurement by immunoassays and binding of digoxin-like immunoreactive components of ginseng with Fab fragment of antidigoxin antibody (Digibind). Am J Clin Pathol 2005;124:229–336.
42. Liao WI, Lin YY, Chu SJ, Hsu CW, Tsai SH. Bradyarrhythmia caused by ginseng in a patient with chronic kidney disease. Am J Emerg Med 2010;28:538.e5–538.e6.